S-003
R(-)-Selegiline solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
别名:
(-)-Deprenyl
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C13H17N
化学文摘社编号:
分子量:
187.28
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
certified reference material
表单
liquid
特点
Snap-N-Spike®/Snap-N-Shoot®
包装
ampule of 1 mL
制造商/商品名称
Cerilliant®
浓度
1.0 mg/mL in methanol
技术
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
应用
clinical testing
包装形式
single component solution
储存温度
−20°C
SMILES字符串
C[C@@H](N(CC#C)C)CC1=CC=CC=C1
InChI
1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1
InChI key
MEZLKOACVSPNER-GFCCVEGCSA-N
基因信息
human ... MAOB(4129)
一般描述
A Certified Spiking Solution® suitable for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis, or urine drug testing. Selegiline is an antidepressant, which belongs to the phenethylamine class of drugs. It is sold under the trade names Anipryl®, Emsam®, and Zelapar® for treatment of Parkinson′s disease, depression, and senile dementia.
法律信息
Anipryl is a registered trademark of Deprenyl Inc.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Emsam is a registered trademark of Somerset Pharmaceuticals, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zelapar is a registered trademark of Valeant Pharmaceuticals North America LLC
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
靶器官
Eyes
储存分类代码
3 - Flammable liquids
WGK
WGK 2
闪点(°F)
49.5 °F - closed cup
闪点(°C)
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Retention rate of selegiline in early Parkinson's disease: a retrospective survey.
T Keränen et al.
International journal of clinical practice, 66(10), 1014-1014 (2012-09-22)
Wakako Maruyama et al.
Journal of neural transmission (Vienna, Austria : 1996), 120(1), 83-89 (2012-08-16)
Neuroprotection has been proposed in neurodegenerative disorders, such as Parkinson's and Alzheimer's diseases, to delay or halt disease progression or reverse neuronal deterioration. The inhibitors of type B monoamine oxidase (MAO), rasagiline and (-)deprenyl, prevent neuronal loss in cellular and
Chi-Un Pae et al.
The Journal of clinical psychiatry, 73(5), 661-668 (2012-06-16)
The objective of this analysis is to present the safety profile of selegiline transdermal system (STS) in clinical practice after US Food and Drug Administration approval by analyzing reported postmarketing adverse events (AEs). Deidentified data were obtained on AEs, regardless
Keiko Inaba-Hasegawa et al.
Journal of neural transmission (Vienna, Austria : 1996), 120(3), 435-444 (2012-09-13)
Type B monoamine oxidase (MAO-B) is proposed to be involved in the pathogenesis of neurodegenerative disorders, such as Parkinson's disease, through oxidative stress and synthesis of neurotoxins. MAO-B inhibitors, rasagiline and selegiline [(-)deprenyl], protect neuronal cells by direct intervention in
Joanna M Krysiak et al.
Angewandte Chemie (International ed. in English), 51(28), 7035-7040 (2012-06-13)
High profile: new activity-based protein profiling (ABPP) probes have been designed that target exclusively monoamine oxidases A and B within living cells (see picture; FAD=flavin adenine dinucleotide, FMN=flavin monodinucleotide). With these probes it could be shown that the MAO inhibitor
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持